☆ 4.5 Letter

Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment

CANCER BIOLOGY & THERAPY (2013)

Journal

CANCER BIOLOGY & THERAPY

Volume 14, Issue 6, Pages 467-468

Publisher

LANDES BIOSCIENCE

DOI: 10.4161/cbt.24346

Keywords

colorectal cancer; cetuximab; body mass index; TTP; FBG; anti-EFGR; cancer

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.